Ligand Announces Positive Preclinical Data on Small-Molecule G-CSF Receptor Agonist at the 55th Annual Meeting of the American Society of Hematology December 9, 2013
Ligand Initiates Phase 1 Trial with Glucagon Receptor Antagonist for Type 2 Diabetes November 12, 2013
Ligand Announces FDA Acceptance of Investigational New Drug Application for Glucagon Receptor Antagonist Program October 7, 2013
Ligand Partner GSK Receives Marketing Authorization from the European Commission for Additional Revolade™ (Eltrombopag) Indication as the First Approved Treatment for Chronic Hepatitis C-Associated Thrombocytopenia September 24, 2013
Ligand Enters Global License Agreement with CURx Pharmaceuticals, Inc. for Captisol-EnabledTM Topiramate Injection August 14, 2013
Ligand Partner GlaxoSmithKline Receives Positive CHMP Opinion for REVOLADE™ in Thrombocytopenia Associated with Chronic Hepatitis C Infection July 26, 2013